Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Condition:   Celiac Disease Interventions:   Drug: Placebo;   Drug: TAK-101;   Dietary Supplement: Gluten Sponsor:   Takeda Not yet recruiting

Source: ClinicalTrials.gov - August 28, 2020 Category: Research Source Type: clinical trials